Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Measuring the clinical response. What does it mean?

P Therasse1

  • 1EORTC Data Center, Av. E. Mounier, 83/11, 1200 Brussels, Belgium. pth@eortc.be

European Journal of Cancer (Oxford, England : 1990)
|September 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Embryotoxicity of human sera from patients treated with isotretinoin.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

European journal of cancer (Oxford, England : 1990)·2008
Same author

Recommendations for the assessment of progression in randomised cancer treatment trials.

European journal of cancer (Oxford, England : 1990)·2008
Same author

Lessons learned from independent central review.

European journal of cancer (Oxford, England : 1990)·2008
Same author

Evaluation of lymph nodes with RECIST 1.1.

European journal of cancer (Oxford, England : 1990)·2008
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Clinical response assessment, using criteria like RECIST, is vital for evaluating anticancer agents. However, its role as a surrogate for survival benefit requires further investigation, especially with novel therapies.

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Background:

  • Clinical response assessment is crucial for evaluating anticancer drug efficacy.
  • Current methods include World Health Organization (WHO) and Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
  • RECIST provides detailed guidance for response evaluation in clinical trials.

Purpose of the Study:

  • To highlight the importance and interpretation of clinical response to anticancer agents.
  • To discuss the role of response evaluation in clinical trials and daily practice.
  • To explore the evolving concepts of clinical benefit with new anticancer therapies.

Main Methods:

  • Review of established criteria for clinical response assessment (WHO, RECIST).
  • Discussion of the application of response evaluation in clinical practice and trials.

Related Experiment Videos

  • Analysis of the limitations and future directions in assessing therapeutic efficacy.

    • Main Results:

    • Clinical response is a key indicator but requires careful interpretation.
    • RECIST criteria offer standardized guidance for response evaluation.
    • The value of clinical response as a surrogate for survival benefit remains uncertain.

    Conclusions:

    • Clinical response assessment is integral to anticancer drug evaluation.
    • Future assessment of clinical benefit must incorporate disease stabilization and time to progression.
    • Biological response assessment may precede clinical response, requiring further research into its predictive value.